Merck confirms efficacy of MS drug Cladribine in post-hoc analysis

Merck Pharmaceuticals has published the results confirming the efficacy of its Cladribine tablets in reducing brain atrophy (volume loss) in patients diagnosed with relapsing remitting multiple sclerosis (RRMS).

The company had already released phase III trial data in the Multiple Sclerosis Journal as part of a study known as CLARITY, but this post-hoc analysis has confirmed these results, demonstrating that Cladribine was significantly more effective than a placebo in further trials.

Additionally, the post-hoc study showed that not only could Cladribine mitigate brain atrophy in RRMS patients, but that it could also improve individuals' chances of remaining free from disability progression over the following two years.

Nicola de Stefano, lead author of the post-hoc paper and a professor of neurology at the University of Siena, commented: "This analysis is important because it confirms the link between reduced brain atrophy and reduced disability progression found in the CLARITY study."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

Image: megaflopp via iStock